BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 4, 2010
View Archived Issues
Four-year COMBAT data detail benefits of Duodart in benign prostatic hyperplasia
Read More
Actelion discloses novel oxazolidinyl antibacterials
Read More
Cancer Research Technology claims novel Wnt signaling inhibitors
Read More
Resolvyx Pharmaceuticals claims novel compounds with antiinflammatory activity
Read More
Pfizer claims novel AMPA receptor agonists
Read More
Schering claims novel alpha2C-adrenoceptor modulators
Read More
Phase I/II results reported for GMI-1070 in sickle cell disease
Read More
Covalent irreversible HCV NS3 protease inhibitors disclosed by Avila Therapeutics
Read More
GI-5005 plus pegIFNalpha-2a/RBV shows clinical potential in chronic HCV patients
Read More
Endotis Pharma's synthetic oligosaccharide EP-80061 shows antitumor activity in animal models
Read More
Sanofi-aventis and Glenmark enter license agreement for chronic pain treatments
Read More
FDA issues complete response letter regarding Bristol-Myers Squibb's BLA for belatacept
Read More
Algeta and Bayer complete sample size re-estimation of ALSYMPCA trial of Alpharadin
Read More
Bicycle Therapeutics signs license agreement with EPFL in Switzerland
Read More
Labopharm and Angelini establish joint venture to commercialize Oleptro
Read More
IRX forms vaccine collaboration with Japan's National Cancer Research Center
Read More
UCB offers Q1 overview
Read More
Jak3 inhibitor R-348 prevents acute rejection and OAD in rodent model of transplantation
Read More
Clinical study, meta-analysis reveal intraocular pressure reductions with PF-4217329
Read More
Repros receives guidance from FDA regarding clinical hold status of Proellex
Read More
Avanir submits complete response to FDA approvable letter for Zenvia
Read More
BioCancell receives FDA approval to continue phase IIb bladder cancer trial
Read More
AlphaRx subsidiary and Pacific Orient form Pacific Orient BioPharma Group
Read More
Althea Technologies acquires Altus' assets and IP portfolio
Read More
Targacept and AstraZeneca amend agreement to expand TC-5619 development program
Read More
Phase III study of TDT-067 for onychomycosis has enrolled first patient
Read More
AG-011 ineffective in phase II ulcerative colitis study
Read More
